These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

198 related articles for article (PubMed ID: 37293150)

  • 1. A novel combination therapy of arginine deiminase and an arginase inhibitor targeting arginine metabolism in the tumor and immune microenvironment.
    Ye PH; Li CY; Cheng HY; Anuraga G; Wang CY; Chen FW; Yang SJ; Lee KT; Chang KY; Lai MD
    Am J Cancer Res; 2023; 13(5):1952-1969. PubMed ID: 37293150
    [TBL] [Abstract][Full Text] [Related]  

  • 2. PEGylated arginine deiminase can modulate tumor immune microenvironment by affecting immune checkpoint expression, decreasing regulatory T cell accumulation and inducing tumor T cell infiltration.
    Brin E; Wu K; Lu HT; He Y; Dai Z; He W
    Oncotarget; 2017 Aug; 8(35):58948-58963. PubMed ID: 28938609
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Selective Intracellular Delivery of Recombinant Arginine Deiminase (ADI) Using pH-Sensitive Cell Penetrating Peptides To Overcome ADI Resistance in Hypoxic Breast Cancer Cells.
    Yeh TH; Chen YR; Chen SY; Shen WC; Ann DK; Zaro JL; Shen LJ
    Mol Pharm; 2016 Jan; 13(1):262-71. PubMed ID: 26642391
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Pegylated recombinant human arginase (rhArg-peg5,000mw) inhibits the in vitro and in vivo proliferation of human hepatocellular carcinoma through arginine depletion.
    Cheng PN; Lam TL; Lam WM; Tsui SM; Cheng AW; Lo WH; Leung YC
    Cancer Res; 2007 Jan; 67(1):309-17. PubMed ID: 17210712
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Down-regulation of argininosuccinate synthetase is associated with cisplatin resistance in hepatocellular carcinoma cell lines: implications for PEGylated arginine deiminase combination therapy.
    McAlpine JA; Lu HT; Wu KC; Knowles SK; Thomson JA
    BMC Cancer; 2014 Aug; 14():621. PubMed ID: 25164070
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Pancreatic cancer cell lines deficient in argininosuccinate synthetase are sensitive to arginine deprivation by arginine deiminase.
    Bowles TL; Kim R; Galante J; Parsons CM; Virudachalam S; Kung HJ; Bold RJ
    Int J Cancer; 2008 Oct; 123(8):1950-5. PubMed ID: 18661517
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Phase 1 trial of ADI-PEG 20 and liposomal doxorubicin in patients with metastatic solid tumors.
    Yao S; Janku F; Koenig K; Tsimberidou AM; Piha-Paul SA; Shi N; Stewart J; Johnston A; Bomalaski J; Meric-Bernstam F; Fu S
    Cancer Med; 2022 Jan; 11(2):340-347. PubMed ID: 34841717
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Phase 1b study of pegylated arginine deiminase (ADI-PEG 20) plus Pembrolizumab in advanced solid cancers.
    Chang KY; Chiang NJ; Wu SY; Yen CJ; Chen SH; Yeh YM; Li CF; Feng X; Wu K; Johnston A; Bomalaski JS; Wu BW; Gao J; Subudhi SK; Kaseb AO; Blando JM; Yadav SS; Szlosarek PW; Chen LT
    Oncoimmunology; 2021; 10(1):1943253. PubMed ID: 34290906
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Pegylated arginine deiminase (ADI-SS PEG20,000 mw) inhibits human melanomas and hepatocellular carcinomas in vitro and in vivo.
    Ensor CM; Holtsberg FW; Bomalaski JS; Clark MA
    Cancer Res; 2002 Oct; 62(19):5443-50. PubMed ID: 12359751
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Renal cell carcinoma does not express argininosuccinate synthetase and is highly sensitive to arginine deprivation via arginine deiminase.
    Yoon CY; Shim YJ; Kim EH; Lee JH; Won NH; Kim JH; Park IS; Yoon DK; Min BH
    Int J Cancer; 2007 Feb; 120(4):897-905. PubMed ID: 17096330
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Arginine Deiminase Induces Immunogenic Cell Death and Is Enhanced by
    Huang Z; Hu H
    Molecules; 2021 Jan; 26(2):. PubMed ID: 33478072
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A role for macrophages under cytokine control in mediating resistance to ADI-PEG20 (pegargiminase) in ASS1-deficient mesothelioma.
    Phillips MM; Pavlyk I; Allen M; Ghazaly E; Cutts R; Carpentier J; Berry JS; Nattress C; Feng S; Hallden G; Chelala C; Bomalaski J; Steele J; Sheaff M; Balkwill F; Szlosarek PW
    Pharmacol Rep; 2023 Jun; 75(3):570-584. PubMed ID: 37010783
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Amino Acid Uptake Measured by [
    Prudner BC; Sun F; Kremer JC; Xu J; Huang C; Sai KKS; Morgan Z; Leeds H; McConathy J; Van Tine BA
    Theranostics; 2018; 8(8):2107-2116. PubMed ID: 29721066
    [No Abstract]   [Full Text] [Related]  

  • 14. Enhancement of anti-tumor activity in melanoma using arginine deiminase fused with 30Kc19α protein.
    Lee H; Park G; Kim S; Son B; Joo J; Park HH; Park TH
    Appl Microbiol Biotechnol; 2022 Nov; 106(22):7531-7545. PubMed ID: 36227339
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Genome-wide CRISPR/Cas9 knockout screening uncovers a novel inflammatory pathway critical for resistance to arginine-deprivation therapy.
    Chu CY; Lee YC; Hsieh CH; Yeh CT; Chao TY; Chen PH; Lin IH; Hsieh TH; Shih JW; Cheng CH; Chang CC; Lin PS; Huang YL; Chen TM; Yen Y; Ann DK; Kung HJ
    Theranostics; 2021; 11(8):3624-3641. PubMed ID: 33664852
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Arginine deprivation by arginine deiminase of Streptococcus pyogenes controls primary glioblastoma growth in vitro and in vivo.
    Fiedler T; Strauss M; Hering S; Redanz U; William D; Rosche Y; Classen CF; Kreikemeyer B; Linnebacher M; Maletzki C
    Cancer Biol Ther; 2015; 16(7):1047-55. PubMed ID: 25774632
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Recombinant human arginase inhibits proliferation of human hepatocellular carcinoma by inducing cell cycle arrest.
    Lam TL; Wong GK; Chong HC; Cheng PN; Choi SC; Chow TL; Kwok SY; Poon RT; Wheatley DN; Lo WH; Leung YC
    Cancer Lett; 2009 May; 277(1):91-100. PubMed ID: 19138817
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Assessment of pegylated arginine deiminase and modified FOLFOX6 in patients with advanced hepatocellular carcinoma: Results of an international, single-arm, phase 2 study.
    Harding JJ; Yang TS; Chen YY; Feng YH; Yen CJ; Ho CL; Huang WT; El Dika I; Akce M; Tan B; Cohen SA; Meyer T; Sarker D; Lee DW; Ryoo BY; Lim HY; Johnston A; Bomalaski JS; O'Reilly EM; Qin S; Abou-Alfa GK
    Cancer; 2021 Dec; 127(24):4585-4593. PubMed ID: 34415578
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The role of arginine and the modified arginine deiminase enzyme ADI-PEG 20 in cancer therapy with special emphasis on Phase I/II clinical trials.
    Synakiewicz A; Stachowicz-Stencel T; Adamkiewicz-Drozynska E
    Expert Opin Investig Drugs; 2014 Nov; 23(11):1517-29. PubMed ID: 24965808
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A phase 1 study of ADI-PEG 20 and modified FOLFOX6 in patients with advanced hepatocellular carcinoma and other gastrointestinal malignancies.
    Harding JJ; Do RK; Dika IE; Hollywood E; Uhlitskykh K; Valentino E; Wan P; Hamilton C; Feng X; Johnston A; Bomalaski J; Li CF; O'Reilly EM; Abou-Alfa GK
    Cancer Chemother Pharmacol; 2018 Sep; 82(3):429-440. PubMed ID: 29971467
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.